Our Team

IMG_3088_edited.png

Kevin Sprott, PhD
 

SVP of Drug Discovery, Co-Founder
Kevin has over 20 years experience as a medicinal chemist leading projects and companies up and through clinical study. Prior to joining Stablix, Kevin provided his expertise to companies such as Syros, Verastem, Ironwood, and Millennium.  Kevin and his teams have delivered 9 development candidates in diverse therapeutic areas, including oncology, immunology and pain.  

Brian Bowman

Brian Bowman, PhD
 

VP of In Vitro Pharmacology, Co-Founder
Brian has over 20 years of research experience as a protein biochemist, biophysicist, and molecular biologist. He's passionate about creating and developing innovative technologies and novel drug discovery platforms while building successful companies.  Prior to Stablix, Brian was a co-founder of WarpDrive Bio and LifeMine Therapeutics and Head of Target Discovery at Inzen Therapeutics. 

scott_headshot.jpg

Scott Kanner, PhD
 

Head of Platform Development, Co-Founder
Scott is driven by targeting common vulnerabilities in disease, with over 10 years of research experience across areas of pharmacology, physiology, cell biology, molecular biology, and protein engineering. He is co-inventor of the company’s foundational platform and heads the research and development of platform technologies at Stablix. As a training physician-scientist at the Medical Scientist Training Program (MSTP) at Columbia University’s Vagelos College of Physicians & Surgeons, Scott received his PhD in Neuroscience and the NIH National Research Service Award.

Uddhav Shigdel, PhD
 

Principal Scientist, Head of Biomolecular Sciences
Uddhav is passionate about drugging the undruggable. He has managed and established teams and laboratory capabilities for chemical synthesis, protein bioscience, protein complex crystallography, biochemical and biophysical assays as a founding scientist in three biotech startups. Notably, he designed first generation compounds for KRAS(G12C)-Cyclophilin A “Tri-Complex” inhibitors at WarpDrive Bio, currently the only compounds in clinical development that inhibit the active form of KRAS(G12C).

Moses Moustakim, DPhil
 

Senior Scientist, Lead Chemist

Moses leads and coordinates the medicinal chemistry efforts across programs at Stablix. He has worked on protein homeostasis regulation and targeted protein degradation, most recently contributing to the discovery of monofunctional and heterobifunctional degraders at C4 Therapeutics, Inc. Moses held a position as a Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, NY and completed his DPhil Organic Chemistry at the University of Oxford, UK.

Yukie Takabatake, PhD

Principal Scientist, Biology

Yukie thrives being at the forefront of science in early-stage biotech companies. She is principal scientist in the biology team, leading efforts on assay development and throughput. Prior to Stablix, Yukie was a principal scientist at Yesse Technologies, Inc., where she ran the bioassay development team aimed at digitizing the sense of smell. She received her PhD in Biomedical Sciences from the Icahn School of Medicine at Mount Sinai and has unique translational expertise in oncology, neuroscience and olfaction research.